News Search Results
Dec 22, 2025, 05:07 ET AusperBio Completes Patient Enrollment in Phase III AUSHINE Study of AHB-137 for Chronic Hepatitis B
2025 /PRNewswire/ -- AusperBio Therapeutics, Inc. and Ausper Biopharma Co., Ltd. (together AusperBio), a clinical-stage biotechnology company developing targeted oligonucleotide therapies for functional cure of chronic hepatitis B (CHB), today announced the completion of patient
More news about: AusperBio Therapeutics Inc.
Dec 22, 2025, 03:00 ET Menarini Silicon Biosystems announces PACE trial biomarker analysis results confirming clinical utility of CELLSEARCH® CTC enumeration to guide treatment decisions in a specific metastatic breast cancer subtype
based in Bologna, Italy, and Huntingdon Valley, Pa., U.S., is a wholly owned subsidiary of the Menarini Group, a multinational pharmaceutical, biotechnology, and diagnostics company headquartered in Florence, Italy, with more than 17,000 employees in 140 countries.[1]
More news about: Menarini Silicon Biosystems
Dec 22, 2025, 03:00 ET Menarini Silicon Biosystems announces PACE trial biomarker analysis results confirming clinical utility of CELLSEARCH® CTC enumeration to guide treatment decisions in a specific metastatic breast cancer subtype
based in Bologna, Italy, and Huntingdon Valley, Pa., U.S., is a wholly owned subsidiary of the Menarini Group, a multinational pharmaceutical, biotechnology, and diagnostics company headquartered in Florence, Italy, with more than 17,000 employees in 140 countries.[1]
More news about: Menarini Silicon Biosystems
Dec 22, 2025, 02:08 ET Mondego Bio Announces Selection of a PTPN2 Inhibitor Clinical Candidate and Targets First-in-Human Trials in H1 2026
CANTANHEDE, Portugal, Dec. 22, 2025 /PRNewswire/ -- Mondego Bio, a clinical-stage biotechnology company developing next-generation small-molecule immuno-oncology therapies, today announced the formal selection of its lead clinical candidate,
More news about: Mondego Bio
Dec 21, 2025, 07:20 ET T-MAXIMUM Pharmaceutical's Allogeneic CAR-T Therapy MT027 Receives FDA IND Clearance to Proceed to Phase II clinical Trial for Recurrent Glioblastoma
feasibility and potential of the company's platform.About T-MAXIMUM PharmaceuticalT-MAXIMUM Pharmaceutical is an innovative biotechnology company dedicated to the development of allogeneic, off-the-shelf cell therapies, with a mission to address diseases for which there are currently
More news about: T-MAXIMUM PHARMACEUTICAL
Dec 19, 2025, 16:26 ET New York State's 2025 Emerging Technology Advisory Board Releases Final Report to Boost Biotech Innovation, Commercialization and Public Health Impact
(AI), the 2025 Board turned the State's attention to the next frontier: biotechnology.This year's ETAB brought together leaders from New York's business, non-profit and research institutions to focus on the broader biotechnology landscape, encompassing closely related sectors such as biopharmaceuticals
More news about: The Michael J. Fox Foundation for Parkinson's Research
Dec 19, 2025, 16:05 ET INOVIO Reports Inducement Grant Under Inducement Plan
PLYMOUTH MEETING, Pa., Dec. 19, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious
More news about: INOVIO Pharmaceuticals, Inc.
Dec 19, 2025, 14:23 ET AMGEN TAKES ACTION WITH THE U.S. GOVERNMENT TO LOWER THE COST OF MEDICINES FOR AMERICAN PATIENTS
to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing
More news about: Amgen
Dec 19, 2025, 08:43 ET Mercury Bio and Meta-Flux Announce Strategic Collaboration to Advance Large-Molecule Therapeutics for Parkinson's and Alzheimer's Diseases
Mercury Bio, a biotechnology company advancing large-molecule therapeutics for neurodegenerative disease, and
More news about: Mercury Bio Inc. & Meta-Flux
Dec 19, 2025, 08:30 ET Xtalks Life Science Podcast Wraps Up 2025 with Deep Dives into Drug Development, Regulation, Clinical Trials and Innovation, Sets Sights on a Transformative 2026 by Xtalks
Throughout 2025, the podcast featured executives, scientists and industry experts from across pharmaceutical, biotechnology, medical device and healthcare organizations. Episodes explored topics ranging from drug development strategy and clinical trial innovation to regulatory
More news about: Xtalks
Dec 19, 2025, 07:45 ET BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook
LINK.About BioMarinBioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based
More news about: BioMarin Pharmaceutical Inc.
Dec 19, 2025, 06:59 ET Probiotic Yeast Market worth $16.23 billion by 2030- Exclusive Report by MarketsandMarkets™
a whole has become an efficient and competent producing medium for probiotic yeast, driven largely by cheap fermentation facilities, a skilled biotechnology workforce, and easy access to the main markets, allowing many firms to scale up production to serve both regional and export markets.The
More news about: MarketsandMarkets
Dec 19, 2025, 03:17 ET Aquaporin updates on strategic review and sets mid-and long-term financial targets
Aquaporin A/S ("Aquaporin" or the "Company"), an innovative water technology company dedicated to rethinking water filtration with biotechnology, hereby updates on its strategic review and provides preliminary 2026 guidance and certain information on its mid- and long-term strategy. Update
More news about: Aquaporin A/S
Dec 19, 2025, 03:16 ET Aquaporin initiates rights issue
Aquaporin A/S ("Aquaporin" or the "Company"), an innovative water technology company dedicated to rethinking water filtration with biotechnology, has resolved to initiate a rights issue with pre-emptive subscription rights (the "Pre-emptive Rights") for the Company's existing shareholders
More news about: Aquaporin A/S
Dec 19, 2025, 03:11 ET Aquaporin initiates rights issue
Aquaporin A/S ("Aquaporin" or the "Company"), an innovative water technology company dedicated to rethinking water filtration with biotechnology, has resolved to initiate a rights issue with pre-emptive subscription rights (the "Pre-emptive Rights") for the Company's existing shareholders
More news about: Aquaporin A/S
Dec 19, 2025, 02:58 ET Aquaporin updates on strategic review and sets mid-and long-term financial targets
Aquaporin A/S ("Aquaporin" or the "Company"), an innovative water technology company dedicated to rethinking water filtration with biotechnology, hereby updates on its strategic review and provides preliminary 2026 guidance and certain information on its mid- and long-term strategy. Update
More news about: Aquaporin A/S
Dec 19, 2025, 00:00 ET MEDIPOST Announces the Exclusive Commercialization License Agreement with Teikoku Seiyaku for Knee Osteoarthritis Treatment CARTISTEM® in Japan
Korea, Dec. 19, 2025 /PRNewswire/ -- MEDIPOST Co., Ltd. (KOSDAQ 078160), a fully integrated cell therapy biotechnology company, today announced a multi-year partnership with Japan's Teikoku Seiyaku Co., Ltd. for the commercialization of CARTISTEM®, an
More news about: MEDIPOST
Dec 18, 2025, 20:26 ET Kodiak Sciences Announces Closing of $184 Million Public Offering of Common Stock including Full Exercise of Underwriters' Option to Purchase Additional Shares
Calif., Dec. 18, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, today announced the closing of its previously announced
More news about: Kodiak Sciences Inc.
Dec 18, 2025, 16:39 ET AdvisorShares Issues Statement on Executive Order to Reclassify Cannabis
regulations related to environmental protection, health and safety. Cannabis-related companies may also be subject to risks associated with the biotechnology and pharmaceutical industries. These risks include increased government regulation, the use and enforcement of intellectual property rights and
More news about: AdvisorShares
Dec 18, 2025, 09:06 ET ATTENTION NASDAQ: SKYE INVESTORS: Contact Berger Montague About a Skye Bioscience, Inc. Class Action Lawsuit
CLICK HERE.Skye, headquartered in San Diego, is a clinical-stage biotechnology company developing treatments for obesity and metabolic diseases.The complaint asserts that, throughout the Class Period, Defendants failed
More news about: Berger Montague
Dec 18, 2025, 09:00 ET Lunai Bioworks (NASDAQ: LNAI) Featured in International Business Times as AI Partnership Talks Advance
valuation re-rating as partnership discussions advanceSeasonal year-end portfolio positioning effects"In biotechnology, strategic partnerships and external validation events are often catalysts that prompt investors to reassess both risk and long-term opportunity,"
More news about: Lunai Bioworks Inc.
Dec 18, 2025, 09:00 ET Century Health and Tessel Biosciences Collaborate to Apply AI-Curated Real World Data to Advance Early Drug Development in COPD
Tessel Biosciences, a biotechnology company that combines human organoids and machine learning to model chronic disease, today announced a collaboration through which Tessel will leverage
More news about: Century Health
Dec 18, 2025, 09:00 ET Freda Key C Presents Advanced Recombinant Collagen Delivery Technology at SCC79
product development. SCC79 is one of the most influential global forums in cosmetic chemistry, bringing together leading scientists, formulators, and biotechnology innovators.
More news about: Shandong Freda Biotech Co., Ltd.
Dec 18, 2025, 07:30 ET Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: SOLIGENIX, INC.
Dec 18, 2025, 07:26 ET Amity University Lucknow Campus Confers Degrees on 1,730 Graduates at 21st Convocation
programmes and more than 7,000 students currently enrolled. Its specialised research centres are active in emerging fields such as nanotechnology, biotechnology, electronics, agriculture and forensic sciences.Addressing the graduates, Dr. Aseem Chauhan, Chairman, Amity University Lucknow Campus, said
More news about: Amity University